Inherited mutations impair responses to environmental carcinogens:  Cancer prevention in mutation carriers by Bernard Friedenson
-1-
Inherited mutations impair responses to en-
vironmental carcinogens:  Cancer prevention 
in mutation carriers  
Bernard Friedenson, Ph.D.
Department of Biochemistry and Molecular Genetics
College of Medicine
900 S Ashland Ave 
University of Illinois Chicago, 
Chicago, IL 60607
Supported by a grant from the University of Illinois Chicago
Running title:
Cancer prevention in mutation carriers  
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.6
02
4.
1 
: P
os
te
d 
11
 J
un
 2
01
1
Abstract
Some environmental carcinogens may be responsible for a modest increase in 
the numbers of cancers after years of exposure.  Economic or political factors weigh 
against widespread bans of carcinogens.  However, lists of chemicals and agents that 
cause cancer assume that everyone is equally susceptible to their carcinogenic effects. 
Hereditary cancer gene mutations can target specific tissues if they are ex-
posed to a carcinogen and the hereditary deficit impairs normal protective responses.  
Mutation carriers should then have higher risks for specific cancers caused by specific 
carcinogens.  
For example, it can be predicted that BRCA1 or BRCA2 mutation carriers 
should be highly susceptible to the carcinogen formaldehyde.   High formaldehyde lev-
els can overwhelm normal enzyme detoxification systems or detoxification genes may 
be inadequate or missing.  Formaldehyde that is not detoxified causes strands of DNA 
to cross-link to each other and to nearby proteins.  Carriers of mutations in BRCA1/2 
dependent pathways are deficient in the ability to undo these cross-links.  
Human myeloid leukemias are linked to formaldehyde.  Inherited biallelic 
BRCA2 gene defects and other defects in BRCA1/2 mediated pathways dramatically 
increase risks for myeloid leukemia, even among infants.  In 12 of 15 studies, hetero-
zygous BRCA1 or BRCA2 mutations increase risks for myeloid leukemias.  Moreover,  
chromosome arms lost in hereditary breast cancers encode enzymes essential for 
formaldehyde metabolism.  BRCA1/2 mutation carriers may reduce their very high 
cancer risks by lowering their exposure to formaldehyde.  
Cancers associated with many other hereditary gene deficits can also be 
stimulated by distinct environmental hazards.  Widespread education could prevent or 
delay some cancers in mutation carriers.   
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Figure 1.  Health effects of formaldehyde exposure in humans and animals [1-6].  Even low level 
exposures by either inhalation or oral ingestion are associated with several types of cancers and 
other health effects in normal individuals.  The levels shown indicate the lowest levels at which the 
indicated health effects have been reported.  The maximum exposure level of 2.0 ppm in the UK 
is larger than permissible levels of 0.75 ppm in the USA and 0.1 ppm in Sweden and Germany. 
Background
Formaldehyde is a direct human mutagen 
and known carcinogen [1-4].   Yet widespread 
human exposures occur during manufacture and 
use of resins, particle board, plywood, leather 
goods, paper, pharmaceuticals, cosmetics, baby 
products, and food.  Latex paint, fingernail cos-
metics,  tobacco smoking, varnishes, floor finishes, 
auto exhaust and organic combustion all release 
formaldehyde.  Nearly 5 million tons of formalde-
hyde were produced in the US in 2003, constitut-
ing 5% of gross national product [1] and repre-
senting a powerful economic force. 
Minimal levels of exposure required 
to produce cancers and other effects on 
health.  Potentially serious common routes of 
exposure to formaldehyde include inhalation, 
from occupational exposure and environment, 
dermal, from occupational handling, and intramus-
cular or subcutaneous from vaccines.      
Fig. 1 gives minimal levels of inhalation and 
oral ingestion associated with cancers and other 
adverse health effects [1-6].  Exposures to 38 
ppm may occur in the plastics industry and to 8.3 
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ppm in biology teaching laboratories.    
Formaldehyde related cancers.  
Nasopharyngeal, sinonasal cancer and myeloid 
leukemia [3, 5] develop at 2 – 5.9 ppm formal-
dehyde in air (Fig. 1).  Nasal epithelium in rats 
contains stem cells that can produce myeloid 
white cells [6].   Inhaled formaldehyde might 
damage these nasal stem cells and cause myeloid 
leukemia. Individuals with nasopharyngeal cancer 
have elevated risks for leukemia and other hema-
tological malignancies.  Genetic susceptibility loci 
for nasopharyngeal cancer are all associated with 
leukemias.   Pathogenic mechanisms in hemato-
logic and nasopharyngeal malignancies may have 
some common features [7].
Mechanisms for formaldehyde 
induced cancers.  Formaldehyde chemically 
cross-links strands of DNA to each other and 
to nearby proteins.  Carriers of mutations in 
BRCA1 or BRCA2 genes are deficient in the 
ability to repair cross-linked DNA.  If cells sur-
vive without correct repairs, then DNA does not 
reproduce properly, further mutations become 
likely and DNA instructions may be misread.  
Chromosome breaks, gains and losses of chro-
mosomes may result.  So BRCA1/2 mutation car-
riers should be at especially high risk for formal-
dehyde related cancers. 
Formaldehyde itself can exist as polymers 
of varying length which may form cross linkers 
with varying reach.  The reactions of formalde-
hyde in DNA-protein mixtures, have been mod-
eled by mixtures of deoxynucleosides and amino 
acids [8]. Cross-linked products that were chemi-
cally irreversible, stable and readily isolated were 
Cys-CH2-dG, Cys-CH2-dA, and Cys-CH2-dC.  
The amino acids Histidine and Tryptophan also 
formed stable cross-links although in lower yield.  
Three lysine cross-linked products were labile in 
solution, supporting widely reported reversibility 
of formaldehyde-induced cross-links between 
lysine rich histones and DNA [8].
Formaldehyde detoxification by 
specialized metabolic pathways.  Normal 
metabolism produces formaldehyde and it oc-
curs naturally in plants, fruits, vegetables, animals 
and seafood.  These sources are generally too 
low to cause permanent harm and are managed 
by reactions and metabolism within the digestive 
tract.   Formaldehyde is primarily metabolized by 
glutathione-dependent formaldehyde dehydro-
genase (ADH3) and aldehyde dehydrogenases 
(ALDHs) enzymes in alternative pathways (Fig. 
2).  Formaldehyde is converted to formate, which 
is then eliminated in the urine as a sodium salt, 
broken down to CO2 and water, or entered into 
the single-carbon pool.    
Deficiencies in any of the enzymes in Fig. 
2 would increase damage from reactive oxygen 
species because unmetabolized formaldehyde 
causes inflammation.  Inhibition of the alcohol 
(ADH) or aldehyde dehydrogenases (ALDH2) 
in Fig. 2 has significant impact on formaldehyde 
toxicity [9].  ADH3 is a member of the alcohol 
dehydrogenase gene family expressed in many 
tissues.   There are different frequencies of ADH3 
alleles among different nationalities. 
DNA cross-links, chromosome breaks 
and chromosome abnormalities are favored by 
saturating formaldehyde metabolizing pathways 
with environmental formaldehyde.   Exogenous 
addition products form between formaldehyde 
and DNA in a highly nonlinear fashion; a 21.7-fold 
increase in exposure caused a 286-fold increase 
in exogenous adducts [10].  As shown below, 
overwhelming formadehyde detoxification is es-
pecially likely to cause chromosomal abnormali-
ties in BRCA1/2 mutation carriers [11]. 
Formaldehyde is more dangerous 
for some people.  One way an inherited cancer 
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Figure 2  - Formaldehyde detoxification mechanisms.  
Detoxification of low levels of formaldehyde occurs primar-
ily by a pathway (thicker arrows) involving formaldehyde 
dehydrogenase (ADH3), an aldehyde dehydrogenase.  The 
pathway converts formaldehyde to formate which is then 
eliminated in the urine, broken down to CO2 and water or 
enters the single carbon pool.  Alternate, less used pathways 
are indicated by thinner arrows [9].  Initial detoxification 
does not involve BRCA1/2.  All the genes encoding the ADH 
enzymes shown are on chromosome 4q which is deleted in 
81% of BRCA1 associated breast cancers [11 ].  Chromosome 
12q containing ALDH2 is deleted in 40%. of BRCA1 associ-
ated breast cancers [11].
gene mutation may target specific tissues is by 
increasing cancer susceptibility to environmen-
tal carcinogens [12]. This theory can be tested 
against risks for cancers associated with formal-
dehyde in BRCA1/2 mutation carriers.  Repair of 
large DNA-protein cross-links caused by form-
aldehyde requires pathways containing normal 
BRCA1 and BRCA2 proteins (Fig. 3, [13,14,12]).  
Current descriptions of an exquisite 
specificity for BRCA1 and BRCA2 mutations in 
causing breast and ovarian cancer require some 
unique, tissue specific property of BRCA1/2    
Loss of BRCA1 mediated 
inhibition of estrogen receptor 
signaling could contribute to 
this specificity [15-17].
An analysis of cancer 
incidence data found that can-
cer targets in BRCA1/2 muta-
tion carriers are in fact not 
exquisitely specific for breast 
and ovary.  There are increased 
risks for cancers in several 
other tissues [18].   Moreover, 
people with compromised 
pathways containing BRCA1/2 
and appropriate risk factors 
are highly prone to develop 
cancers mediated by some 
organ specific inflammatory 
infections.   In these cases, the 
cancer targets are determined 
by the organ specific infections 
and not by the BRCA mutation 
[12,19].  All tissues are prob-
ably unduly susceptible to car-
cinogens if the carcinogens can 
exploit the inherited deficit.  
All tissues have inherited pre-
mutated (cancer) stem cells. 
Methods
As previously described [12,18,19], the 
literature was systematically searched for relative 
risk data on second primary cancers in carriers 
or likely carriers of mutations in BRCA1/2 genes.   
Data found in appropriate studies was used 
directly in Table 1 without combining.  No exclu-
sions were made for percentages of mutation 
carriers in the population, for survival, or for loss 
of subjects to follow-up.  
Testing formaldehyde associated 
cancer risks in mutation carriers.  Of nu-
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merous environmental carcinogens that can 
exploit deficits in the pathways in Fig 3, form-
aldehyde is among the most abundant and best 
studied.  Six different major and independent 
criteria (Tests 1-6 below) were devised and used 
to evaluate risks for formaldehyde associated 
cancers in mutation carriers (tests 1-6 in results 
and discussion).
Results and Discussion
Test 1.  Mutation carriers have wide-
ly varying cancer risks.  Female mutation car-
riers have high risks for breast /ovarian cancer as 
a group but individual risks within this group vary 
greatly.  There is no single risk associated with 
BRCA1 or BRCA2 carrier status [20].  Defective 
BRCA genes increase risks for cancers in organs 
other than breast and ovary but individual muta-
tion carriers again differ greatly [18]. These results 
implicate an increased susceptibility in organs 
exposed to environmental carcinogens and/or 
deficits in additional genes [12].
 Test 2.  BRCA1/2 gene mutations 
are associated with myeloid leukemia.  In-
herited mutations in BRCA1/2, Fanconi anemia 
and ATM genes share the ability to compromise 
the pathways in Fig. 3, hindering complex repairs 
needed to remove DNA-protein cross-links, and 
to control aberrant DNA rearrangements [21].   
These mutations are all associated with leukemias, 
especially myeloid leukemias.  This association 
is especially strong for homozygous or biallelic 
mutations in BRCA2 (Fanconi protein D1).  Six 
children with biallelic BRCA2 mutations all devel-
oped leukemia at median age 2.2 years, with 4 of 
6 developing acute myeloid leukemia (AML) [22].
Biallelic BRCA2 mutation patients have a 79% cu-
mulative probability of leukemia (primarily AML) 
by age 10 years ([23] and Table 1).  
Homozygous or biallelic mutations 
Figure 3  - BRCA1 and BRCA2 in pathways to 
repair DNA damage caused by formaldehyde 
and other DNA damaging agents.
BRCA1 and BRCA2 are shown in pathways 
to correct DNA cross links and double strand 
breaks caused by formaldehyde.  DNA dam-
age is more likely if formaldehyde escapes 
metabolic detoxification (as shown in Fig. 2).  
Fanconi proteins and ATM are also shown 
within these pathways.  Hereditary inactiva-
tion of a Fanconi gene causes Fanconi ane-
mia,  inactivation of the ATM gene causes 
ataxia-telangiectasia (A-T), and inactivation 
of BRCA1 or BRCA2 associates with heredi-
tary breast/ovarian cancers.  Proteins en-
coded by genes related to these well known 
hereditary cancer conditions are colored red 
[14, 12].  The pathway may be defective in 
CML and ubiquitin (Ub) is not added to Fan-
coni protein D2 (see text). Some chemother-
apy drugs may have similar effects but data 
in Table 1 do not support chemotherapy for 
breast cancer as the major cause of excess 
AML in mutation carriers.
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in BRCA1 are incompatible with human life 
but heterozygous BRCA1 mutations are well 
known.  Carriers of heterozygous mutations in 
either BRCA1 or BRCA2 have increased risks 
for myeloid leukemia  Table 1 summarizes risks 
for myeloid leukemia from 15 studies (A - O) 
of heterozygous BRCA1/2 mutation carriers or 
individuals eligible for mutation testing.  12 of the 
15 studies reported risks for leukemia or myeloid 
leukemia that are elevated by at least 50%.  Risks 
may be even greater because none of the 15 
studies included populations that had all tested 
positive for mutation and data was not corrected 
for mortality.  
Test 2.  Mutations in other genes 
encoding the BRCA1/2 pathway (Fig. 3) 
are associated with myeloid leukemia and 
would prevent correct repair of formalde-
hyde damage.  Other hereditary cancer related 
conditions are also associated with homozygous 
or biallelic mutations in genes encoding proteins 
within the model pathway (Fig. 3).   These condi-
tions are Fanconi anemia caused by inactivation 
of one of 13 Fanconi anemia genes and ataxia-
telangiectasia (A-T) caused by inactivation of the 
ATM gene.   
Mutations in Fanconi anemia genes.  
In Fanconi anemia patients, summary relative 
risks for AML were 703.3 [363.7–1354.5] [21].   
This suggests that functional Fanconi proteins are 
essential to prevent AML [24].   Few stringent 
genotype–phenotype connections have emerged 
for Fanconi anemia.  This suggests other genes 
and environmental factors modify the phenotype 
[25].
Mutations in Fanconi genes contribute 
to a subset of sporadic AML [26-28].  In hetero-
zygous carriers, lymphocytes show increased 
sensitivity to mutagens, but are not blocked in G2 
phase as in full Fanconi Anemia [29,30].   Hetero-
zygous mutation in the Fanconi J gene prevents 
the encoded helicase from unwinding DNA [31], 
suggesting one mechanism.    
Other relationships exist between leuke-
mias and the pathway in Fig 3.   A characteristic 
fusion protein (BCR/ABL) is found in AML (and 
in CML) that interferes with the formation of 
nuclear FANCD2 foci (Fig 3), but this interfer-
ence can be reversed by the ectopic expression 
of BRCA1[32].
Mutations in the ATM gene (Fig. 3) 
may increase risks for myelod leukemias.  
In addition to requiring BRCA and Fanconi 
proteins, complex DNA damage (and replica-
tion fork stalling) also activate ATM (Fig. 3).  ATM 
modulates the loading of recombinational repair 
proteins onto translocation breakpoint hotspots.  
This protects against inappropriate recombina-
tion and translocations characteristic of myeloid 
leukemias [33].   The checkpoint in Fig. 3 stabiliz-
es the genome by stopping the cell cycle so that 
cells with damaged DNA can complete repairs.  
In AML,  activated ATM fails to engage this check-
point [34].  There are isolated reports of AML 
associated with ATM mutation.  
Test 3.  Formaldehyde causes some 
DNA damage that requires the path-
way in Fig. 3.  Many studies show mutations 
in BRCA1/2 dependent pathways compromise 
repair of DNA damage from cross-linking agents.  
Laboratory experiments with cells show that 
formaldehyde is one of these cross-linking agents. 
Repairing the complex DNA damage it causes 
requires BRCA1, BRCA2 (Fanconi protein D1), 
and 13 other Fanconi proteins (Fig. 3) [13].
DNA-protein cross-links exhibit a dose-
response relationship to formaldehyde exposure 
in the respiratory tract of laboratory animals 
at exposure concentrations relevant to human 
exposures.  In peripheral white blood cells of 
occupationally exposed workers,  DNA-protein 
cross-links increased significantly vs controls and 
had a linear relationship with years of exposure 
[35].
BRCA1/2 related pathways also partici-
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Table 1 Risks of leukemia and oral cavity cancers as cancers following breast, ovarian or fallopian tube 
cancer in proven or potential BRCA1/2 mutation carriers
Reference number and Study 
population
Mutation test status
Risk measurement for leukemias 
[Confidence interval]
Risk for phar-
ynx, sinus or 
nose cancer 
6 children with biallelic BRCA2 muta-
tions [25].
Biallelic BRCA2 mutations (com-
pound heterozygotes)
All developed leukemia at median age 
2.2 years.  4 of 6 AMLs 
Review of 27 biallelic BRCA2 muta-
tion patients [26]. 
Biallelic BRCA2 mutations (com-
pound heterozygotes)
79% cumulative probability of leukemia 
(primarily AML) by age 10 years  
22 oropharyn-
geal cancers in 
59 patients
A. First breast cancer age <45 in 6958 
Connecticut women. 
Potential mutation carriers eligible 
for mutation testing
Acute non-lymphocytic leukemia as 2nd 
cancer O/E=2.9 at 1-4 years and 6.4 at 
5-9 years 
1.9 (buccal cavity, 
pharynx)
B. 279,745 primary breast cancer 
patients, age 35-49,  Finnish Cancer 
Registry (1953-1979) 
Potential mutation carriers eligible 
for mutation testing
Subsequent leukemia (excluding CLL) 
RR= 3.21 p<.01 NR
C. 82,520 Women with breast cancer 
age <=45 in 13 cancer registries. 
Potential mutation carriers eligible 
for mutation testing
Myeloid Leukemia  SIR = 3.02 (2.32–
3.85) Leukemia SIR = 2.16 (1.78–2.59). 1.40 [1.21–1.61]
D. Female breast cancer in Denmark 
(1943-80) surviving >= 10 years 
(selects 11,273 younger surviving 
patients). 
Potential mutation carriers eligible 
for mutation testing
Acute non-lymphocytic leukemia as a 2nd 
cancer RR=2.3 +#
E. 2,084 Women with primary fallopian 
tube cancer . Probable BRCA1/2 mutation carriers. 
Non-lymphoid leukemia RR=3.7 (1.0-
9.4) 1.4 [1.1–1.6]
F. Women with 2 breast or ovarian can-
cers in Thames Cancer Registry . 
Potential BRCA1/2 mutation carriers 
eligible for mutation testing Myeloid leukemia RR=5.04 [1.85-11.0] 14.7 [1.73 -51.6] 
G. 2nd cancer after Breast Cancer<50. 
Potential BRCA1/2 mutation carriers 
eligible for mutation testing Myeloid leukemias RR=2.31 [1.52-3.51] 0.96
H. 2nd cancer after male breast cancer at 
1-9 yrs of follow up. 
Men at high risk for being (BRCA2) 
mutation carriers eligible for muta-
tion testing
Myeloid leukemia 3.98 [1.46 – 8.67] 1.25 [0.50 – 2.57]
I. 291 first degree relatives of BRCA1 
probands with ovarian cancer 
Tested BRCA1 heterozygotes or 
potential carriers eligible for testing
Leukemias, lymphomas, etc RR=3.7 
(1.5 to 9.5)  (2006); RR= 2.6 [1.02-6.6] 
(2001).
NR
J. 11 BRCA1+BRCA2 mutation carriers.
Known BRCA1 and BRCA2 muta-
tion carriers
20% (2/11) leukemias as 2nd primary in 1 
BRCA1 and 1 BRCA2 carrier.  +*
K. 3678 women, 50 men 1st degree rela-
tives of mutation carriers or of breast 
or ovarian cancer patients  
471 BRCA2 carriers, 390 noncarriers, 
and 2186 unknown BRCA2 carrier 
status 
Leukemia RR= 1.12 [0.30–4.25] 2.26 [1.09-4.58]
L. 11847 individuals from 699 families 
segregating a BRCA1 mutation .
18.9% (2245) tested BRCA1 carriers, 
9.3% (1106) tested negative, 71.7% 
(8496) untested.  
Leukemia RR = 0.88 [0.37 to 2.14] p=.83 +** 
M. 1811 male and female family members. 
50% probability BRCA2 mutation 
from 139 BRCA2 families. Leukemia RR= 1.5 [0.5 to 3.5] 2.4
N. 728 individuals male and female 
From families with an identified 
BRCA2 mutation with and without 
breast cancer history
Acute leukemia 1.54 [0.04±8.59] Oral cavity 4.17 [0.11±23.26]
O. 1145 individuals male and female  From BRCA1-associated families Acute leukemia 1.01 [0.03±5.62] NR
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pate in preventing formaldehyde related collat-
eral DNA damage.  This includes increased cell 
proliferation (which increases the probability that 
damaged cells will multiply and acquire further 
errors), bone marrow toxicity and immunosup-
pression (which can reactivate latent viral infec-
tions), and inflammation (which can produce 
cross-links due to oxidative damage).  
Test 4.  Pharynx associated cancers 
in mutation carriers.  Formaldehyde is impli-
cated in very rare nasopharyngeal and sinona-
sal cancers [3,6]. The annual incidence of nasal 
tumors in the United States is < 1 in 100,000 
people per year.  Such rare outcomes are difficult 
to study due to a lack of statistical power. 
Nasal sinus cancer occurred among 
2245 known BRCA1 carriers and 8496 untested 
relatives(Table 1, study L).   Two “nose cancers” 
were found among 471 known heterozygous 
BRCA2 carriers and 2186 untested family mem-
bers. (Table 1, study K)  One of two buccal cavity 
cancers in 1160 relatives of A-T patients was 
nasopharyngeal cancer in a 6 year old[36]. In 
addition to causing cancer itself, formaldehyde 
might facilitate human papilloma virus (HPV) 
infections by damaging both the epithelial barrier 
and immunity.  HPV infection has been implicated 
in oropharyngeal cancer,  a site where nasal sinus 
cancer originates.  The gene for the formaldehyde 
scavenger ADH3 may even be lost in HPV associ-
ated tumors [37].  
Computational models predict the nose 
absorbs approximately 90% of inhaled formalde-
hyde at resting inspiration.  The exposure of oral 
cavity structures to formaldehyde markedly in-
creases during heavy exercise,  [38] as breathing 
shifts to oral.   Cancers of the oral cavity are the 
most frequent solid tumors in Fanconi homozy-
gotes with relative risk >200 times normal [23, 
21].   For heterozygotes or potential heterozy-
gotes (Table 1), most studies report some in-
crease in risks for cancers within the oral cavity.  
Different incidences of cancers linked 
to formaldehyde in different environments.  
Geographic variation in nasopharyngeal carcinoma 
reflects a complex etiology of several subtypes.  It 
is not currently possible to separate environmen-
tal,  viral (Epstein Barr virus), and genetic compo-
nents as first or second hits.  High to intermediate 
rates in endemic areas contrast markedly with the 
uniformly rare rates seen in most of the world 
[39].  Leukemia rates also differ substantially for 
different racial and ethnic groups living exposed 
to different levels of environmental formaldehyde.  
Leukemia incidence is lowest among American 
Indians/Alaskan natives (6.5 per 100,000).  
Test 5.  Comparisons of chromo-
some abnormalities.  Greater numbers of 
DNA-protein cross-links were found in breast 
cancer patients than in matched controls [40] 
and formaldehyde has been positively associated 
with breast cancer risk [41].  It is well known that 
BRCA1/2 related pathways help protect against 
chromosome losses.  81% of BRCA1 deficient 
breast tumors lose chromosome 4q [11].  Simi-
larly 40% of BRCA1 deficient breast cancers have 
lost chromosome 12q [11].  These losses were 
much more common than in control tumors.  The 
human alcohol dehydrogenase genes essential for 
formaldehyde detoxification are found in a cluster 
on chromosome 4q, and ALDH2 is found on chro-
mosome 12q (Fig. 2).  Loss of either chromosome 
4q or 12q destroys genes for the main protective 
metabolic pathways (Fig. 2) that protect against 
formaldehyde.  Either loss then may accelerate 
latent and occult breast tumors.  
Fanconi anemia patients with AML and 
myelodysplastic syndrome commonly lose one 
copy of chromosome 7.   Formaldehyde exposure 
associates with chromosome 7 loss in the stem/
progenitor cells where leukemia may originate [1].  
Losses of genetic material from chromo-
some 5 and chromosome 7 common in myeloid 
leukemias are also associated with hereditary 
breast cancers.  86% of BRCA1 associated breast 
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tumors lost chromosome 5q [11] and 27% of 
BRCA2 breast cancers lost a marker on chro-
mosome 7 [42].  The inherited gene defects may 
also facilitate loss of one copy of chromosome 
17, containing BRCA1 and p53 genes.  In myeloid 
leukemias, chromosome 17 is frequently lost or 
involved in complex chromosomal abnormalities 
including balanced translocations involving the 
BRCA1 locus [43].  These observations suggest 
some pathogenic mechanisms in leukemias may 
be related to those in hereditary breast cancers.   
Test 6.  Treatment related risk fac-
tors for myeloid leukemia.   In the studies 
in Table 1, most of the excess risk for AML is 
probably not due to therapy for breast cancer.   
AML occurs with virtual certainty in children and 
infants with biallelic mutations in BRCA2.  AML 
also occurs at very young ages in Fanconi anemia 
patients, before any chemotherapy or radiation 
has been given.  Moreover defects in pathways 
requiring normal BRCA gene function are as-
sociated with other hematopoietic malignancies 
that are not generally considered to be therapy 
related [21].
The first chemotherapy regimen for 
breast cancer was not published until 1975 with 
large trial results appearing in 1976 [44].   The 
first three studies in Table 1 include patients 
diagnosed with breast cancer before adjuvant 
chemotherapy became widely used.  In compari-
son to later studies, the three pre-chemotherapy 
studies in Table 1 do not show less risk for AML.   
In one early study, women over 55 had no excess 
risk for any second cancer while women younger 
than 55 still had over 3 times the risk for myeloid 
leukemia [Table 1 Study A].  Neither group was 
unlikely to receive routine chemotherapy.  The 
observation of approximately the same risk for 
AML before and after 1975 is not compatible 
with the fact that chemotherapy was given to a 
larger proportion of breast cancer patients dur-
ing later periods [Table 1, Study C].   
A few of the more recent studies in Table 
1 show no excess risk for myeloid leukemia, con-
sistent with environmental or additional genetic 
variation.   Relative risks for myeloid leukema if 
platinum chemotherapy was likely to be used are 
not substantially higher (Table 1, studies E and F).   
Moreover both studies E and F reported elevated 
risks for cancers of the pharynx region, perhaps 
related to inhalation or facilitated HPV infection.
Radiation therapy.  Therapeutic doses 
of targeted field radiation causes very little or no 
increased risk of myeloid cancers.  This is consis-
tent with myeloid stem cells being more radiation 
resistant than non-stem cells [45, 46].
Despite younger ages, breast cancer 
patients with BRCAI/2 mutations present at a 
similar stage, display a normal acute reaction 
to radiotherapy and have a similar prognosis 
compared to sporadic breast cancer patients  
[47].   An increased risk of radiation therapy 
related-AML is largely confined to young women 
with stage III breast cancer, (spread to lymphoid 
tissue).  These patients are more likely to receive 
radiation in some combination with cytotoxic 
chemotherapy.  In stage 1 disease, radiation is 
given alone and there is very little excess risk for 
AML [48].  Nonetheless sound arguments remain 
to limit radiation exposure in mutation carriers.
Other inherited cancer asso-
ciated conditions and envi-
ronmental carcinogens.
Table 2 gives additional examples of 
inherited cancer associated conditions that have 
increased susceptibility to environmental carcino-
gens.   Common findings are increased sensitiv-
ity to cancer associated infections, to radiation, 
and to chemical carcinogens.  This shows that 
the phenomenon of increased sensitivity to the 
environmental carcinogen formaldehyde is prob-
ably representative of a broad general phenome-
non.  Further studies of the relationship between 
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genetic inheritance and environmental cancer 
susceptibility are needed. 
Clinical Significance 
 Genetic conditions affect susceptibility 
to carcinogens.   Avoiding specific mutagens that 
crosslink DNA may reduce cancer risk for those 
with mutations affecting BRCA1/2 pathways.   
Activity of alcohol and aldehyde dehydrogenase 
enzymes should further stratify risk.   Other 
common DNA damaging agents [benzopyrene, 
hexavalent chromium, etc] might also cause 
undue cancer risks.   Identifying distinct environ-
mental hazards may prevent other hereditary 
cancer conditions.   
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Major hereditary tu-
mor types, organ Gene / Pathway
Hereditary 
Syndrome(s)
Examples of known or suspected risk factors, carcinogens, patho-
gens, inflammation, infection
Colon, thyroid, stomach 
intestine APC /APC FAP
Increased sensitivity to viral transformation [1] Viral proteins strongly pro-
mote hepatoblastoma [2] (750 - 7500 times normal risk with most before 
age 3 years.   Increased risk for medulloblastoma with polyoma virus JCV [3].  
Anti-inflammatory drugs reduce number and size of polyps.
Colon MUTYH / BER Polyposis
Oxidizing agents in colon.  Defect linked to repair of oxidized guanine in DNA 
(8-oxoguanine DNA)[4]
Colon uterus
MSH2, MLH1, 
MSH6, PMS2 /
MMR
HNPCC
Inflammation (Anti inflammatories markedly reduce risk)[5], cigarette smok-
ing [6].
Small Intestine, stomach, 
colon ovary, pancreas
STK11 (LKB1)/
PI3K Peutz-Jeghers syndrome
Increased sensitivity to viral transformation [1] Mutations involved in a subset 
of HBV related hepatocellular carcinoma [7]
Thyroid, breast, gliobas-
toma, melanoma, pros-
tate carcinoma, endome-
trial carcinoma
PTEN
Bannayan-Riley-Ruvalcaba 
syndrome, Bannayan-Zonana 
syndrome, Riley-Smith syn-
drome, Ruvalcaba-Myhre-Smith 
syndrome, Macrocephaly, Pseu-
dopapilledema, Multiple heman-
giomata, Macrocephaly, Multiple 
lipomas, Hemangiomata
PTEN is targeted by cancer associated pathogens HCV, HBV, HPV and 
h.pylori.  
Skin, medulloblastoma PTCH /GLI or
SUFU /GLI
Gorlin syndrome,
Medulloblastoma predisposi-
tion
The human polyomaviruses JC virus (JCV) is associated with glial tumors 
and pediatric medulloblastomas [8,3] Report of thousands of tumors ap-
pearing after radiation therapy[9]
Table 2.  Examples of hereditary cancer syndromes with known sensitivity to specific environmental carcinogens.
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Major hereditary tu-
mor types, organ Gene / Pathway
Hereditary 
Syndrome(s)
Examples of known or suspected risk factors, carcinogens, patho-
gens, inflammation, infection
Malignant melanoma 
basal cell and squa-
mous cell carcinoma
XPA, C; ERCC2–5; 
DDB2 /NER
Xeroderma pigmentosum UV light 
Lymphomas, leukemias, 
solid tumors, breast 
cancers, 
A-T, NBS, DNA 13 
FA genes including 
BRCA2, BRCA1
Ataxia telangiectasia
Nijmegan breakage syn-
drome, Fanconi anemia, 
Fanconi pancytopenia
Infection/inflammation, DNA crosslinking agents such as mitomycin, acet-
aldehyde from alcohol metabolism.   Early radiation exposure from chest 
x-rays in BRCA1 carriers is a risk factor for breast cancer [10].
Lymphomas
Fas gene, Fas re-
ceptor, caspase 10, 
8 genes, cyclin D1,  
ATM
Chronic lymphoproliferative 
disorder, Wiskott-Aldridge, 
common variable immuno-
deficiency, A-T
Immunosuppressive treatments.  HIV, HHV8, EBV, HTLV, h.pylori infection  
Agricultural, petrochemical, firefighting occupation.  
Leukemias, lymphomas, 
HNSCC, breast cancer, 
carcinomas and broad 
spectrum of cancers
recQ helicase Bloom syndrome Sun, radiation, papilloma virus infection, carcinogens including tobacco, alcohol
AML,  juvenile myelo-
monocytic leukemias,
neuroblastoma, mela-
noma, , breast cancer, 
lung cancer, colorectal 
cancer.
PTPN11, codes for 
phosphatase Shp2
LEOPARD syndrome, 
NOONAN syndrome, 
Cardiocutaneous syndrome,  
Multiple-lentigines syndrome
Deregulates response to inflammatory cytokines. Viral infections present 
in 2/3 of children with juvenile myelomoncytic leukemia at diagnosis [11]  
SHP2 may serve as part of an initial protective mechanism against UV skin 
carcinogenesis [12]
Thyroid, melanoma, 
soft tissue sarcoma 
Osteosarcoma
WRN/CIN heli-
case? belonging to 
recQ family
Werner Syndrome
Human herpesvirus 8 [Kaposis sarcoma] Sarcomas often start in areas of 
the body that had been treated with radiation.  Fibroblasts are unusually 
sensitive to the DNA damaging agent 4-nitroquinoline 1-oxide  [13]
Leukemias CBP/p300
Broad thumb  hallux syn-
drome, Rubinstein-Taybi 
syndrome
Many viral oncoproteins have been found to modulate p300/CBP function. 
These include Ad E1a, SV40 LT, HPV E6, HPV E7, EBV EBNA2, HTLV Tax and 
HIV Tat[14]
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Major hereditary tu-
mor types, organ Gene / Pathway
Hereditary 
Syndrome(s)
Examples of known or suspected risk factors, carcinogens, patho-
gens, inflammation, infection
Osteosarcoma, skin 
cancer
RECQL4 helicase
Rothmund Thompson syn-
drome
Sites of bone infarcts, metallic prostheses and prior internal fixation. Ioniz-
ing radiation, intravenous radium and Thorotrast.  Alkylating agents may also 
contribute, apparently independent of radiotherapy [15].
CNS hemangioblasto-
mas; renal cell carcino-
mas; pheochromocy-
tomas; pancreatic islet 
cell tumors; endolym-
phatic sac tumors. 
VHL / HIF1 Von Hippel−Lindau syn-
drome
High-level exposure to trichloroethylene and reactive metabolites are geno-
toxic to kidney proximal tubule. This is a tumor-initiating process linked 
with mutational changes in the VHL tumor suppressor gene [16]
Wilms’ kidney WT1 /p53 Familial Wilms tumor Hair coloring products, vaginal infections, tea drinking, prenatal pesticides.  
Breast, sarcoma, adre-
nal, brain.
TP53 (p53)/ p53 Li-Fraumeni syndrome Virtually all DNA tumor viruses that cause tumors in experimental animals or humans encode proteins that inactivate both Rb and p53 [17]
Eye RB1 /RB Hereditary retinoblastoma Virtually all DNA tumor viruses that cause tumors in experimental animals or humans encode proteins that inactivate both Rb and p53 [17]
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